# National Hospital Organization Kyushu Cancer Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-hospital-organization-kyushu-cancer-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 50.3 |
| Citations | 295,426 |
| City | Fukuoka |
| Country | JP |
| Description | National Hospital Organization Kyushu Cancer Center is a research organisation in Fukuoka, JP. OpenAlex records 4,978 works and 295,426 citations for it. 604 researchers list it as their most recent affiliation. |
| Homepage | http://www.ia-nkcc.jp/ |
| OpenAlex ID | https://openalex.org/I4210093709 |
| Researchers | 604 |
| ROR ID | https://ror.org/00mce9b34 |
| Type | healthcare |
| Works | 4,978 |

## University papers

Showing 12 of 30.

- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-fusion-positive-non-small-cell-lung-cancer/)
- [Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study](https://scholariq.org/papers/lorlatinib-in-patients-with-alk-positive-non-small-cell-lung-cancer-results-from/)
- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study](https://scholariq.org/papers/ch5424802-ro5424802-for-patients-with-alk-rearranged-advanced-non-small-cell/)
- [Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-ros1-fusion-positive-non-small-cell-lung-cancer-integrated/)
- [Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/prophylactic-cranial-irradiation-versus-observation-in-patients-with-extensive/)
- [Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer](https://scholariq.org/papers/exosomal-microrna-in-serum-is-a-novel-biomarker-of-recurrence-in-human/)

## University researchers

- [Hideki Nakayama](https://scholariq.org/researchers/hideki-nakayama/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.